Sermorelin + GHRP-2 – 5mg / 5mg (3ml Pen)

Sermorelin + GHRP-2 5mg/5mg (3ml Pen) – Dual Growth Hormone Research Peptide Blend

Sermorelin + GHRP-2 is a dual-peptide research formulation combining a growth hormone-releasing hormone (GHRH) analogue with a synthetic growth hormone secretagogue. Each compound interacts with a different receptor system involved in regulating pituitary growth hormone secretion.

Sermorelin corresponds to the biologically active 29-amino-acid region of human GHRH, while GHRP-2 activates the growth hormone secretagogue receptor GHS-R1a, also known as the ghrelin receptor.

The combination is particularly relevant to scientific investigations examining complementary endocrine signalling, growth hormone regulation and interactions between hypothalamic and pituitary pathways.

Supplied in a 3ml pen containing 5mg of Sermorelin and 5mg of GHRP-2, this formulation belongs to the Coridion Sciences research peptide collection.

Understanding the Sermorelin and GHRP-2 Combination

Growth hormone secretion is regulated by several interacting hormonal systems rather than a single signalling pathway.

Two important regulators are growth hormone-releasing hormone and ghrelin receptor-mediated signalling.

Sermorelin and GHRP-2 allow these pathways to be investigated together.

Sermorelin – GHRH Receptor Activation

Sermorelin is a synthetic peptide corresponding to human GHRH(1-29)-NH2. It stimulates GHRH receptors on pituitary somatotroph cells, activating intracellular signalling mechanisms associated with growth hormone secretion.

GHRP-2 – Ghrelin Receptor Activation

GHRP-2 is a synthetic growth hormone secretagogue that activates GHS-R1a receptors. These receptors influence growth hormone secretion through signalling mechanisms distinct from those activated by GHRH.

Because the compounds act on different receptor systems, their combined activity has become an important subject of endocrine research.

Sermorelin + GHRP-2 and Muscle Growth Research

Growth hormone participates in biological processes associated with skeletal muscle physiology, protein metabolism and tissue development.

Research involving GHRH analogues and growth hormone secretagogues provides insight into the mechanisms governing endogenous growth hormone secretion and downstream endocrine responses.

The Sermorelin + GHRP-2 combination is relevant to studies examining:

• Growth hormone secretion: Investigating hormonal responses following simultaneous GHRH and ghrelin receptor activation.
• Muscle physiology: Exploring growth hormone-related pathways involved in skeletal muscle tissue regulation.
• Protein metabolism: Studying endocrine mechanisms associated with protein turnover and tissue development.
• IGF-1 signalling: Examining relationships between growth hormone secretion and insulin-like growth factor activity.
• Pituitary function: Investigating interactions between different growth hormone regulatory pathways.
• Metabolic regulation: Understanding how growth hormone-related signalling contributes to energy metabolism.

Although these pathways are associated with muscle development, clinical evidence does not establish that this specific combination improves muscle mass, physical strength, recovery or athletic performance in humans.

Researchers investigating related compounds can explore our wider collection of growth hormone and muscle performance research peptides, including compounds studied for their roles in endocrine regulation, muscle physiology and metabolic signalling.

Mechanism of Action

GHRH Receptor Signalling

Sermorelin binds to growth hormone-releasing hormone receptors located on anterior pituitary somatotroph cells.

Receptor activation stimulates the Gs protein signalling pathway, increasing intracellular cyclic adenosine monophosphate (cAMP).

Downstream mechanisms contribute to growth hormone secretion and the regulation of pituitary cell activity.

This process resembles an important component of natural hypothalamic control over growth hormone release.

Ghrelin Receptor Signalling

GHRP-2 interacts with the growth hormone secretagogue receptor GHS-R1a.

Its activation influences intracellular calcium signalling and other mechanisms involved in stimulating growth hormone secretion.

The receptor is also involved in broader physiological processes, including appetite regulation and energy balance.

GHRP-2 can influence additional endocrine responses, including ACTH, cortisol and prolactin under certain experimental conditions.

Interaction Between the Two Pathways

One of the principal reasons for studying Sermorelin and GHRP-2 together is their distinct receptor activity.

Experimental studies involving GHRH and GHRP-2 have demonstrated that combined stimulation can produce greater growth hormone responses than either compound alone.

Some investigations have reported synergistic effects, although findings depend on experimental conditions, hormonal status and the amounts of each compound studied.

These results support the scientific relevance of dual-pathway research but do not establish the efficacy of this particular fixed-dose formulation.

Somatostatin and Growth Hormone Regulation

Somatostatin is an important inhibitory regulator of pituitary growth hormone secretion.

Research has investigated how growth hormone secretagogues interact with somatostatin-mediated inhibition and other regulatory mechanisms.

The balance between stimulatory and inhibitory signalling influences the magnitude and timing of growth hormone responses.

Understanding these interactions is an important objective of combination peptide research.

Scientific Research Applications

1. Dual-Receptor Growth Hormone Research

Sermorelin and GHRP-2 engage separate receptor systems involved in growth hormone secretion.

Their combined investigation provides a model for studying how different signalling pathways interact within the growth hormone axis.

2. Pituitary Function and Endocrine Responses

Both GHRH analogues and growth hormone secretagogues have been investigated in pituitary function research.

Studies involving these compounds have examined growth hormone secretory capacity, pituitary responsiveness and the effects of different hormonal stimuli.

3. Growth Hormone and IGF-1 Regulation

Growth hormone influences insulin-like growth factor-1 production in the liver and other tissues.

IGF-1 participates in biological processes involving cellular growth, tissue development and metabolic regulation.

Investigating the upstream mechanisms controlling growth hormone secretion contributes to understanding this broader endocrine system.

4. Receptor Pharmacology and Hormonal Selectivity

GHRH receptors and ghrelin receptors activate different intracellular pathways.

Research involving their combined stimulation contributes to understanding receptor interactions, signalling specificity and additional hormonal responses.

GHRP-2’s effects on cortisol and prolactin are particularly relevant when assessing endocrine selectivity.

5. Muscle Physiology and Protein Metabolism

Growth hormone signalling has an established relationship with skeletal muscle physiology and protein metabolism.

Experimental investigations involving Sermorelin and GHRP-2 may help clarify the upstream endocrine processes associated with these pathways.

However, increased circulating growth hormone does not necessarily translate into improved muscle strength or performance.

Sermorelin + GHRP-2 Compared with Related Peptide Combinations

Different growth hormone research combinations may activate similar biological pathways but differ in their molecular characteristics.

Sermorelin + GHRP-2

Combines the active 29-amino-acid GHRH fragment with a ghrelin receptor agonist. Research interest centres on complementary receptor stimulation and pituitary growth hormone responses.

Sermorelin + GHRP-6

Uses the same GHRH analogue alongside GHRP-6, a secretagogue particularly associated with appetite-related signalling in experimental research.

CJC-1295 No DAC + GHRP-2

Combines a modified GHRH analogue with GHRP-2. Unlike Sermorelin, CJC-1295 No DAC incorporates structural modifications intended to improve resistance to enzymatic degradation.

CJC-1295 No DAC + Ipamorelin

Combines a modified GHRH analogue with Ipamorelin, a compound investigated for comparatively selective growth hormone secretion in preclinical models.

These distinctions are important when comparing molecular stability, receptor pharmacology and endocrine research findings.

Sermorelin + GHRP-2 Product Specifications

• Product: Sermorelin + GHRP-2
• Quantity: 5mg Sermorelin + 5mg GHRP-2
• Format: 3ml pen
• Classification: GHRH analogue and growth hormone secretagogue combination
• Sermorelin structure: 29-amino-acid GHRH fragment
• Primary receptors: GHRH receptor (GHRHR) and growth hormone secretagogue receptor (GHS-R1a)
• Primary research focus: Growth hormone secretion and dual-receptor endocrine signalling
• Additional research areas: Pituitary physiology, IGF-1 regulation, muscle physiology and receptor pharmacology
• Research status: Investigational combination

Research Peptide Combinations from Coridion Sciences

Coridion Sciences supplies specialist research peptides and combination formulations for laboratory and scientific investigation.

Its research catalogue includes individual compounds and peptide blends studied across endocrine regulation, cellular signalling, metabolic physiology and growth hormone biology.

Sermorelin + GHRP-2 5mg/5mg is supplied in a 3ml pen format as part of the company’s peptide combination range.

Research Use Only: This formulation is intended exclusively for scientific and laboratory research. It is not approved for human consumption, medical treatment, muscle-building therapy

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

GHRP-2 potency

Comparative studies ranking release magnitude above the selective agonists.

Diagnostic context

Both constituents have been used as provocative agents in pituitary function research.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.